Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Imatinib(Gleevec®) in Selected Patients With Metastatic Melanoma

NCT00881049 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT00881049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00881049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Imatinib(Gleevec®) in Selected Patients With Metastatic Melanoma
Lead sponsor
Peking University
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2008
Completion date
January 31, 2011
Enrollment
1 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma